A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.

Inclusion Criteria:

• Prior treatment with at least 2 anti-hypertensive medications, at optimal or besttolerated dose, of different pharmacological classes, including a diuretic,
• Participants with uncontrolled blood pressure (mean sitting systolic blood pressure of 140 mmHg or greater) and chronic kidney disease stage 3 or 4 (estimated GlomerularFiltration Rate of at least 15 and below 60 mL/min/1.73m2 using the Chronic KidneyDisease-Epidemiology equation),
• Women of childbearing potential are eligible only if the following applies:
• Negative pregnancy test at the screening visit and at baseline (i.e., end ofrun-in period).
• Agree to undertake pregnancy tests during the study and up to 30 days afterrandomized study treatment discontinuation.
• Agree to use highly-effective methods of contraception up to at least 30 daysafter study treatment discontinuation.

Exclusion Criteria:

• Mean sitting systolic blood pressure above 170 mmHg measured by "automated officeblood pressure measurement" (AOBPM),
• Mean sitting diastolic blood pressure above 105 mmHg measured by AOBPM,
• Change in renal function requiring hospitalization, documented eGFR decline of greaterthan 20% in the 3 months prior to the screening visit, dialysis in the 3 months beforethe screening visit,
• Planned dialysis or kidney transplant during the course of this study,
• Nephrotic syndrome defined as urine albumin-to-creatinine ratio above 3000 mg/g,
• Known and documented chronic heart failure.